• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cancer-associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer.

作者信息

Xia Zihan, Vermeulen Stephanie, Suwal Ujjwal, Rappu Pekka, Heino Jyrki, De Vuyst Felix, Dedeyne Sandor, Hendrix An, Denys Hannelore, De Wever Olivier

机构信息

Department of Human Structure and Repair, Laboratory of Experimental Cancer Research, Ghent University, Ghent, Belgium.

Cancer Research Institute Ghent, Ghent, Belgium.

出版信息

Clin Transl Med. 2024 Jul;14(7):e1779. doi: 10.1002/ctm2.1779.

DOI:10.1002/ctm2.1779
PMID:39032166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11260170/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/361546f1835a/CTM2-14-e1779-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/803a9a9d81d1/CTM2-14-e1779-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/4364c732abe9/CTM2-14-e1779-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/a4cb992f19f4/CTM2-14-e1779-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/361546f1835a/CTM2-14-e1779-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/803a9a9d81d1/CTM2-14-e1779-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/4364c732abe9/CTM2-14-e1779-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/a4cb992f19f4/CTM2-14-e1779-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77bb/11260170/361546f1835a/CTM2-14-e1779-g001.jpg

相似文献

1
Cancer-associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer.癌症相关成纤维细胞介导乳腺癌对新辅助治疗的耐药性。
Clin Transl Med. 2024 Jul;14(7):e1779. doi: 10.1002/ctm2.1779.
2
New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.乳腺癌新辅助化疗耐药研究新进展。
Int J Mol Sci. 2021 Sep 6;22(17):9644. doi: 10.3390/ijms22179644.
3
Novel module and hub genes of distinctive breast cancer associated fibroblasts identified by weighted gene co-expression network analysis.基于加权基因共表达网络分析鉴定的具有独特乳腺癌相关成纤维细胞的新型模块和枢纽基因。
Breast Cancer. 2020 Sep;27(5):1017-1028. doi: 10.1007/s12282-020-01101-3. Epub 2020 May 1.
4
Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.靶向治疗调节癌症相关成纤维细胞的分泌组以诱导 HER2 阳性乳腺癌的耐药性。
Int J Mol Sci. 2021 Dec 10;22(24):13297. doi: 10.3390/ijms222413297.
5
Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.基质细胞特征与局部晚期乳腺癌新辅助化疗反应相关。
Cells. 2019 Dec 4;8(12):1566. doi: 10.3390/cells8121566.
6
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer.炎症成纤维细胞介导直肠癌对新辅助治疗的抵抗。
Cancer Cell. 2022 Feb 14;40(2):168-184.e13. doi: 10.1016/j.ccell.2022.01.004. Epub 2022 Feb 3.
7
Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.针对骨膜蛋白研发工程化肽拮抗剂以克服乳腺癌多柔比星耐药性。
BMC Cancer. 2021 Jan 14;21(1):65. doi: 10.1186/s12885-020-07761-w.
8
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.肿瘤相关成纤维细胞通过激活 FGFR2 促进 HER2 靶向治疗耐药。
Clin Cancer Res. 2020 Mar 15;26(6):1432-1448. doi: 10.1158/1078-0432.CCR-19-0353. Epub 2019 Nov 7.
9
Sensitivity to Cisplatin in Head and Neck Cancer Cells Is Significantly Affected by Patient-Derived Cancer-Associated Fibroblasts.头颈部癌细胞对顺铂的敏感性受患者来源的癌相关成纤维细胞的显著影响。
Int J Mol Sci. 2021 Feb 15;22(4):1912. doi: 10.3390/ijms22041912.
10
Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.血小板激活外渗和 Podoplanin 阳性癌相关成纤维细胞对胰腺癌基质的影响。
Anticancer Res. 2019 Oct;39(10):5565-5572. doi: 10.21873/anticanres.13750.

引用本文的文献

1
Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective.乳腺癌对新辅助化疗的耐药性：代谢视角
J Exp Clin Cancer Res. 2025 Aug 11;44(1):234. doi: 10.1186/s13046-025-03500-w.

本文引用的文献

1
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
2
EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions.乳腺癌转移和耐药性中的 EMT 机制：重新审视分子相互作用和生物学功能。
Biomed Pharmacother. 2022 Nov;155:113774. doi: 10.1016/j.biopha.2022.113774. Epub 2022 Oct 3.
3
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
新辅助化疗后残余肿瘤负担与乳腺癌长期生存结局：5161 例患者的多中心汇总分析。
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.
4
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review.分子生物标志物预测乳腺癌患者新辅助化疗的病理完全缓解：综述
Cancers (Basel). 2021 Oct 31;13(21):5477. doi: 10.3390/cancers13215477.
5
A framework for advancing our understanding of cancer-associated fibroblasts.推进我们对癌症相关成纤维细胞理解的框架。
Nat Rev Cancer. 2020 Mar;20(3):174-186. doi: 10.1038/s41568-019-0238-1. Epub 2020 Jan 24.
6
Unmasking senescence: context-dependent effects of SASP in cancer.揭示衰老：SASP 在癌症中的上下文相关效应。
Nat Rev Cancer. 2019 Aug;19(8):439-453. doi: 10.1038/s41568-019-0156-2. Epub 2019 Jun 24.
7
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.乳腺癌的病理完全缓解和长期临床获益：CTNeoBC 汇总分析。
Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14.
8
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.肿瘤-基质相互作用在改变药物反应中的作用：挑战与机遇。
Nat Rev Drug Discov. 2013 Mar;12(3):217-28. doi: 10.1038/nrd3870.
9
Accessories to the crime: functions of cells recruited to the tumor microenvironment.肿瘤微环境中募集的细胞的功能：犯罪的帮凶。
Cancer Cell. 2012 Mar 20;21(3):309-22. doi: 10.1016/j.ccr.2012.02.022.
10
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.乳腺癌新辅助与辅助全身治疗的荟萃分析
J Natl Cancer Inst. 2005 Feb 2;97(3):188-94. doi: 10.1093/jnci/dji021.